MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance on
common stock, net of...
$29,498K
Proceeds from exercise of
options
$2,763K
Net cash provided by
financing activities
$32,261K
Net increase
(decrease) in cash and cash...
-$393,026K
Canceled cashflow
$32,261K
Stock-based compensation
$15,006K
Accounts payable and
accrued...
$7,657K
Prepaid expenses and
other assets
-$5,281K
Accounts payable and
accrued...
$2,803K
Non-cash lease expense
$895K
Net amortization of
premiums and discounts on...
-$301K
Depreciation
$105K
Net cash used in
investing activities
-$318,453K
Net cash used in
operating activities
-$106,834K
Canceled cashflow
$32,048K
Purchases of marketable
securities
$318,173K
Purchase of property and
equipment
$280K
Net loss
-$137,950K
Operating lease
liabilities
-$932K
Back
Back
Cash Flow
source: myfinsight.com
Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Inc. (BCAX)